SNDX
Syndax Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.17B
P/E Ratio
—
EPS
$-3.29
Beta
0.41
52W High
$25.59
52W Low
$8.58
50-Day MA
$22.23
200-Day MA
$17.21
Dividend Yield
—
Profit Margin
-165.60%
Forward P/E
—
PEG Ratio
0.00
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $172.35M |
| Gross Profit (TTM) | $-93.40M |
| EBITDA | $-273.48M |
| Operating Margin | -91.60% |
| Return on Equity | -161.80% |
| Return on Assets | -27.30% |
| Revenue/Share (TTM) | $1.99 |
| Book Value | $0.74 |
| Price-to-Book | 34.34 |
| Price-to-Sales (TTM) | 12.57 |
| EV/Revenue | 12.48 |
| EV/EBITDA | -105.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 795.00% |
| Shares Outstanding | $88.20M |
| Float | $74.69M |
| % Insiders | 1.81% |
| % Institutions | 116.51% |
Historical Volatility
HV 10-Day
55.37%
HV 20-Day
41.37%
HV 30-Day
44.60%
HV 60-Day
43.88%
HV Rank
10.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($39.00 target)
2
Strong Buy10
BuyData last updated: 4/9/2026